Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IgA

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Study title: Clinical Study to Investigate the Efficacy and Tolerability of Acarbose (BAY g 5421) Versus Placebo in Diabetic Children (PH 23433)
    Active substance: ACARBOSE
    Study summary document link (including results): Bayer Pharma_Acarbose_0634_study_synopsis.pdf
    View full study record
    Document reference: 46155
    Study title: Salicylémie chez le nourisson hyperthermique (évolution des taux plasmatiques après absorption de salicylés) - D. Rigal, E. Hartemann, P. Baltassat-1982
    Active substance: ACETYL SALICYLIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46176
    Study title: Ballmer−Weber−B−K, Gex−Collet−C, Wüthrich−B. Inhibition of histamine or allergen−induced wheals by a single dose of acrivastine, fexofenadine or cetirizine. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología, Nov−Dec 1999, vol. 9, no. 6, p. 351−5.Ballmer−Weber−B−K, Gex−Collet−C, Wüthrich−B. Inhibition of histamine or allergen−induced wheals by a single dose of acrivastine, fexofenadine or cetirizine. Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología, Nov−Dec 1999, vol. 9, no. 6, p. 351−5.
    Active substance: ACRIVASTIN
    Study summary document link (including results):
    View full study record
    Document reference: 46229
    Study title: A MULTI-CENTER, INVESTIGATOR-MASKED, RANDOMIZED, ACTIVE CONTROLLED, PARALELL GROUP SUPERIORITY STUDY TO COMPARE THE CLINICAL EFFICACY OF ADAPALENE GEL, 0.3% VERSUS ADAPALENE GEL, 0.1%, IN THE TREATMENT OF ACNE VULGARIS - PHASE III
    Active substance: ADAPALENE
    Study summary document link (including results):
    View full study record
    Document reference: 46279
    Study title: A MULTICENTER, RANDOMIZED, INVESTIGATOR-BLINDED, PARALLEL GROUP COMPARISON OF ADAPALENE GEL (CD271G) 0.1% AND ITS VEHICLE IN THE TREATMENT OF ACNE VULGARIS - PHASE III
    Active substance: ADAPALENE
    Study summary document link (including results):
    View full study record
    Document reference: 46290
    Study title: A STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ZENTEL IN THE TREATMENT OF INTESTINAL HELMINTHIASIS IN KENYAN CHILDREN LESS THAN 2 YEARS OF AGE
    Active substance: ALBENDAZOLE
    Study summary document link (including results): Study AL-MEA-0172-Albendazole.xls
    View full study record
    Document reference: 46322
    Study title: An open label study to investigate the pharmacokinetic profile of alendronate in paediatric patients with osteogenesis imperfecta.
    Active substance: ALENDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46328
    Study title: An Open-Labeled Study to Investigate the Pharmacokinetic Profile of Alendronate in Glucocorticoid-Treated Pediatric Patients
    Active substance: ALENDRONIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46326
    Study title: International clinical study to investigate the incidence of inhibitors in previously untreated patients with severe haemophilia A treated with Octate (=Wilate).
    Active substance: ALGINIC ACID COMBINATIONS
    Study summary document link (including results):
    View full study record
    Document reference: 46426
    Study title: The use of silicones as an approach to the management of infantile colic. Dugger J.A., Inchaustegui S.R., J. Michigan State Medical Soc. 62, 46-49, 1963. The use of silicones as an approach to the management of infantile colic. Dugger J.A., Inchaustegui S.R., J. Michigan State Medical Soc. 62, 46-49, 1963.
    Active substance: ALGELDRATE + MAGNESIUM HYDROXIDE + SIMETICONE/ ALDEGRATE+ MAGNESIUM HYDROXIDE
    Study summary document link (including results):
    View full study record
    Document reference: 46393
    Study title: Pharmacoclinical investigation of the DA hypothesis in child autism with Amisulpride and Bromocriptine - Dollfus S. - 15/11/1989
    Active substance: AMISULPRIDE
    Study summary document link (including results):
    View full study record
    Document reference: 21683
    Study title: "Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meat-analysis of individual data from 6500 patients in randomised trials. - ATMA investigators. - 1997 (Lancet, 350: 1417-1424) ; - Publicati" "Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meat-analysis of individual data from 6500 patients in randomised trials. - ATMA investigators. - 1997 (Lancet, 350: 1417-1424) ; - Publicati"
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45201
    Study title: An Open-Label Study to Investigate the Pharmacokinetics of Losartan in Hypertensive Children and Infants
    Active substance: AMPICILLIN AND SULBACTAM
    Study summary document link (including results):
    View full study record
    Document reference: 21776
    Study title: Pharmacoclinical investigation of the DA hypothesis in child autism with Amisulpride and Bromocriptine - Dollfus S. - 15/11/1989
    Active substance: AMISULPRIDE
    Study summary document link (including results):
    View full study record
    Document reference: 21685
    Study title: "Clinical efficacy and safety of intravenous amiodarone in infants and children. - Figa FH et al. - 1994 (Am. J. Cardiol., 74: 573-577) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -" "Clinical efficacy and safety of intravenous amiodarone in infants and children. - Figa FH et al. - 1994 (Am. J. Cardiol., 74: 573-577) ; - Publication in CES EXPCRC-CES0172-EN01, CES EXPCRC-CES0173-EN01, CES EXPCRC-CES0206-EN01 -"
    Active substance: AMIODARONE
    Study summary document link (including results):
    View full study record
    Document reference: 45194
    Study title: A multi-investigator randomized trial comparing the efficacy of BMY28100 versus amoxicillin/clavulanate potassium in the treatment of acute otitis media in children.
    Active substance: AMOXICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 46587
    Study title: A randomized, investigator blinded, multicenter, comparative study of cefprozil versus high dose amoxicillin/clavulanate in the treatment of otitis media in children.
    Active substance: AMOXICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 46589
    Study title: A randomized, investigator blinded, multicenter, comparative study of Gatifloxacin versus amoxicillin/clavulanate in the treatment of recurrent otitis media and acute otitis media treatment failures in children.
    Active substance: AMOXICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 46591
    Study title: A randomized, investigator blinded, multicenter, comparative study of Gatifloxacin versus high dose amoxicillin/clavulanate in the treatment of recurrent otitis media and acute otitis media treatment failures in children.
    Active substance: AMOXICILLIN
    Study summary document link (including results):
    View full study record
    Document reference: 46590
    Study title: A Randomized , Investigator-Blind, Multicenter Study to Asses the efficacy of Oral AUGMENTIN ES-600 Twice Daily for 10 days Versus Oral Zithromax Once daily for 5 days in the treatment of Acute Otitis Media in Infants and Children
    Active substance: AMOXICILLIN AND CLAVUNALIC ACID
    Study summary document link (including results):
    View full study record
    Document reference: 46631
    1  2  3  4  5  6  7  8  9  Next» Last»»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 18 12:43:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA